The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, provides an update on an ongoing phase I/II study (NCT02596971) evaluating the safety and efficacy of atezolizumab combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Results are encouraging and comparable to those previously reported for R-CHOP. Dr Younes explains how the outcomes where compared to those from the GOYA study (CT01287741). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
